GlassScriptPhysician profile
Kyungmee Kim
NPI 1518954957
$68,093.43
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $4,727 · 2021: $7,719 · 2022: $12K · 2023: $8,857 · 2024: $4,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,278 · Consulting Fee: $3,600 · Travel and Lodging: $1,084 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,277.61 |
| Consulting Fee | $3,600.00 |
| Travel and Lodging | $1,084.22 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $46,887.38 | 2019-2024 | Arikayce |
| Astrazeneca Pharmaceuticals LP | $4,542.74 | 2019-2024 | Airsupra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $4,319.40 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,035.96 | 2019-2024 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Regeneron Healthcare Solutions, INC. | $1,606.08 | 2019-2024 | Dupixent |
| Amgen INC. | $1,364.48 | 2019-2024 | Tezspire, Repatha |
| Abbvie INC. | $1,354.09 | 2019-2024 | |
| Genzyme Corporation | $561.68 | 2020-2024 | |
| Advanced Respiratory, INC | $392.26 | 2020-2021 | |
| Electromed, INC. | $390.98 | 2021-2024 | Smartvest |
| Genentech USA, INC. | $387.08 | 2019-2022 | |
| Philips North America LLC | $338.83 | 2019-2024 | (Ak6) Vest Therapy |
| Merck Sharp & Dohme LLC | $327.07 | 2019-2024 | Keytruda |
| Novo Nordisk INC | $254.98 | 2019-2024 | Ozempic, Rybelsus |
| Mallinckrodt Hospital Products INC. | $224.99 | 2021-2023 | Acthar |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $218.96 | 2020-2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $215.84 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $199.36 | 2019-2021 | |
| Lilly USA, LLC | $190.83 | 2019-2023 | Mounjaro |
| Daiichi Sankyo INC. | $160.26 | 2024 | Injectafer |
| Amarin Pharma, INC. | $149.67 | 2019-2021 | |
| Baxter Healthcare | $149.50 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Janssen Pharmaceuticals, INC | $139.19 | 2019-2020 | |
| Pulmonx Corporation | $125.00 | 2019 | |
| Olympus America INC. | $125.00 | 2022 | |
| Sunovion Pharmaceuticals INC. | $105.13 | 2019-2021 | |
| Inogen, INC. | $87.39 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Biohaven Pharmaceutical Holding Company LTD. | $68.79 | 2022 | |
| Exact Sciences Corporation | $59.42 | 2023-2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $24.24 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.54 | 2019 | |
| Sumitomo Pharma America, INC. | $21.96 | 2024 | Gemtesa |
| United Therapeutics Corporation | $21.40 | 2024 | Tyvaso |
| Circassia INC. | $20.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyungmee Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.